A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation
Clinical trial NCT06546280 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06546280
- Sponsor
- Zhujiang Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-08-26
- Primary completion
- 2026-08-26
- Enrollment
- 38
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.